356 related articles for article (PubMed ID: 30858012)
21. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
22. Oral Aripiprazole as Maintenance Treatment in Adolescent Schizophrenia: Results From a 52-Week, Randomized, Placebo-Controlled Withdrawal Study.
Correll CU; Kohegyi E; Zhao C; Baker RA; McQuade R; Salzman PM; Sanchez R; Nyilas M; Carson W
J Am Acad Child Adolesc Psychiatry; 2017 Sep; 56(9):784-792. PubMed ID: 28838583
[TBL] [Abstract][Full Text] [Related]
23. Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.
Wang LJ; Ree SC; Huang YS; Hsiao CC; Chen CK
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():260-6. PubMed ID: 23085073
[TBL] [Abstract][Full Text] [Related]
24. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
Loy JH; Merry SN; Hetrick SE; Stasiak K
Cochrane Database Syst Rev; 2012 Sep; (9):CD008559. PubMed ID: 22972123
[TBL] [Abstract][Full Text] [Related]
25. Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.
Juncal-Ruiz M; Ramirez-Bonilla M; Gomez-Arnau J; Ortiz-Garcia de la Foz V; Suarez-Pinilla P; Martinez-Garcia O; Neergaard KD; Tabares-Seisdedos R; Crespo-Facorro B
Psychopharmacology (Berl); 2017 Sep; 234(17):2563-2570. PubMed ID: 28567698
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial.
Findling RL; McKenna K; Earley WR; Stankowski J; Pathak S
J Child Adolesc Psychopharmacol; 2012 Oct; 22(5):327-42. PubMed ID: 23083020
[TBL] [Abstract][Full Text] [Related]
27. Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach.
Castro-Fornieles J; Parellada M; Soutullo CA; Baeza I; Gonzalez-Pinto A; Graell M; Paya B; Moreno D; de la Serna E; Arango C
J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):327-36. PubMed ID: 18759642
[TBL] [Abstract][Full Text] [Related]
28. No Differences in Weight Gain Between Risperidone and Aripiprazole in Children and Adolescents After 12 Months.
Schoemakers RJ; van Kesteren C; van Rosmalen J; Eussen MLJM; Dieleman HG; Beex-Oosterhuis MM
J Child Adolesc Psychopharmacol; 2019 Apr; 29(3):192-196. PubMed ID: 30672720
[TBL] [Abstract][Full Text] [Related]
29. Weight-Change Trajectories of Pediatric Outpatients Treated with Risperidone or Aripiprazole in a Naturalistic Setting.
Pozzi M; Pisano S; Marano G; Carnovale C; Bravaccio C; Rafaniello C; Capuano A; Rossi F; Rizzo R; Bernardini R; Nobile M; Molteni M; Clementi E; Biganzoli E; Radice S
J Child Adolesc Psychopharmacol; 2019 Mar; 29(2):133-140. PubMed ID: 30452281
[TBL] [Abstract][Full Text] [Related]
30. Leukocytopenia in patients treated with multiple antipsychotics, including aripiprazole and quetiapine.
Tomita T; Goto H; Chiba T; Tairabune T; Yoshida T; Tanaka K; Kudo K; Kohda Y
Psychiatry Clin Neurosci; 2017 Jan; 71(1):71-72. PubMed ID: 27743457
[No Abstract] [Full Text] [Related]
31. Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia.
Barber S; Olotu U; Corsi M; Cipriani A
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD006324. PubMed ID: 28333365
[TBL] [Abstract][Full Text] [Related]
32. Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses.
Moreno C; Merchán-Naranjo J; Alvarez M; Baeza I; Alda JA; Martínez-Cantarero C; Parellada M; Sánchez B; de la Serna E; Giráldez M; Arango C
Bipolar Disord; 2010 Mar; 12(2):172-84. PubMed ID: 20402710
[TBL] [Abstract][Full Text] [Related]
33. Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial.
Johnsen E; Kroken RA; Løberg EM; Rettenbacher M; Joa I; Larsen TK; Reitan SK; Walla B; Alisauskiene R; Anda LG; Bartz-Johannessen C; Berle JØ; Bjarke J; Fathian F; Hugdahl K; Kjelby E; Sinkeviciute I; Skrede S; Stabell L; Steen VM; Fleischhacker WW
Lancet Psychiatry; 2020 Nov; 7(11):945-954. PubMed ID: 33069317
[TBL] [Abstract][Full Text] [Related]
34. A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder.
Honer WG; MacEwan GW; Gendron A; Stip E; Labelle A; Williams R; Eriksson H;
J Clin Psychiatry; 2012 Jan; 73(1):13-20. PubMed ID: 21733490
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.
McEvoy JP; Lieberman JA; Perkins DO; Hamer RM; Gu H; Lazarus A; Sweitzer D; Olexy C; Weiden P; Strakowski SD
Am J Psychiatry; 2007 Jul; 164(7):1050-60. PubMed ID: 17606657
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic effectiveness and tolerability of aripiprazole as initial choice of treatment in first episode psychosis in an early intervention service: A one-year outcome study.
Malla A; Mustafa S; Rho A; Abadi S; Lepage M; Joober R
Schizophr Res; 2016 Jul; 174(1-3):120-125. PubMed ID: 27157800
[TBL] [Abstract][Full Text] [Related]
37. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.
Mukundan A; Faulkner G; Cohn T; Remington G
Cochrane Database Syst Rev; 2010 Dec; (12):CD006629. PubMed ID: 21154372
[TBL] [Abstract][Full Text] [Related]
38. Metabolic Effects of 7 Antipsychotics on Patients With Schizophrenia: A Short-Term, Randomized, Open-Label, Multicenter, Pharmacologic Trial.
Zhang Y; Wang Q; Reynolds GP; Yue W; Deng W; Yan H; Tan L; Wang C; Yang G; Lu T; Wang L; Zhang F; Yang J; Li K; Lv L; Tan Q; Li Y; Yu H; Zhang H; Ma X; Yang F; Li L; Chen Q; Wei W; Zhao L; Wang H; Li X; Guo W; Hu X; Tian Y; Ren H; Ma X; Coid J; Zhang D; Li T;
J Clin Psychiatry; 2020 Mar; 81(3):. PubMed ID: 32237292
[TBL] [Abstract][Full Text] [Related]
39. Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics.
Fraguas D; Merchán-Naranjo J; Laita P; Parellada M; Moreno D; Ruiz-Sancho A; Cifuentes A; Giráldez M; Arango C
J Clin Psychiatry; 2008 Jul; 69(7):1166-75. PubMed ID: 18588363
[TBL] [Abstract][Full Text] [Related]
40. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
